Kiniksa Pharmaceuticals International

Company snapshot

Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for different

• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 14 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Kiniksa Pharmaceuticals International. Not investment advice.

• Peer + 0 momentum

  Cardiol Therapeutics

  TA overlap score 22.2

Recent activity

Latest pipeline, patent, and corporate events for Kiniksa Pharmaceuticals International.

1. Jun 8, 2026 Clinical update

   KPL-404-C221 — Phase 2

2. Jun 8, 2026 Clinical update

   Mavrilimumab — Phase 2

3. Jun 8, 2026 Clinical update

   mavrilimumab — Phase 3

4. Jun 5, 2026 Clinical update

   KPL-387 — Phase 2

5. Jun 5, 2026 Clinical update

   mavrilimumab — Phase 2

View all clinical trial activity →

• What is Kiniksa Pharmaceuticals International?

  Kiniksa Pharmaceuticals is a pharma organization headquartered in Lexington, USA. It trades on NYSE under ticker KNSA. Primary therapeutic focus areas include Recurrent Pericarditis, Sjögren’s Disease, Well-Controlled Recurrent Pericarditis, Sjögrens Disease, Pericarditis. NovaPh

• Is Kiniksa Pharmaceuticals International publicly traded?

  Yes. Kiniksa Pharmaceuticals International is listed with ticker KNSA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Kiniksa Pharmaceuticals International develop or market?

  We link 7 drug profile(s) where Kiniksa Pharmaceuticals International is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc#company-drugs.

• What are the latest developments for Kiniksa Pharmaceuticals International?

  In the last 12 months our linked public records show 14 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Kiniksa Pharmaceuticals International focus on?

  Kiniksa Pharmaceuticals International focuses on Recurrent Pericarditis, Sjögren’s Disease, Well-Controlled Recurrent Pericarditis based on our analysis of their pipeline programs and drug development activities.